Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Harrison, OK
Chad Harrison, Tulsa, OK US
| Patent application number | Description | Published |
|---|---|---|
| 20090230015 | Home pharmacy kits - A package set is provided. The package set includes a holder; a container removably coupled to the holder; and a correlator including at least one container label coupled to the container and at least one holder label coupled to the holder, each container label and each holder label includes a description portion and an indicator, the indicator of the holder label is substantially identical to the indicator of the container label to facilitate matching at least one container to at least one holder. | 09-17-2009 |
| 20110120904 | HOME PHARMACY KITS - A package set is provided. The package set includes a holder; a container removably coupled to the holder; and a correlator including at least one container label coupled to the container and at least one holder label coupled to the holder, each container label and each holder label includes a description portion and an indicator, the indicator of the holder label is substantially identical to the indicator of the container label to facilitate matching at least one container to at least one holder. | 05-26-2011 |
Chad E. Harrison, Tulsa, OK US
| Patent application number | Description | Published |
|---|---|---|
| 20080228160 | ESSENTIAL HOME PHARMACY KITS - A home pharmacy kit provided to organize, educate, simplify and add convenience to the consumer regarding self-treatment with over-the-counter (OTC) drugs and self-management of therapy with widely and commonly used OTC medications. The kit of the invention allows a consumer to achieve appropriate therapy when self-medicating and allows a consumer to avoid therapeutic duplication and over utilization and/or underutilization of medications, which may result from a lack of consumer related to the action and effects of common active ingredients found in a wide variety of cold and cough combination drug products as well as in gastrointestinal combination drug products. | 09-18-2008 |
Maria Harrison, Ardmore, OK US
| Patent application number | Description | Published |
|---|---|---|
| 20090113569 | ROOT-SPECIFIC PHOSPHATE TRANSPORTER PROMOTERS - The current invention provides plant promoter sequences. Compositions comprising the promoter sequence are described, as are methods for the expression of transgenes in plants comprising the use of these sequences. The methods of the invention include the direct creation of transgenic plants with the promoters by genetic transformation, as well as by plant breeding methods. | 04-30-2009 |
| 20090113571 | ROOT-SPECIFIC PHOSPHATE TRANSPORTER PROMOTERS - The current invention provides plant promoter sequences. Compositions comprising the promoter sequence are described, as are methods for the expression of transgenes in plants comprising the use of these sequences. The methods of the invention include the direct creation of transgenic plants with the promoters by genetic transformation, as well as by plant breeding methods. | 04-30-2009 |
Roger G. Harrison, Norman, OK US
| Patent application number | Description | Published |
|---|---|---|
| 20080227687 | COMPOSITION AND METHOD FOR CANCER TREATMENT USING TARGETED SINGLE-WALLED CARBON NANOTUBES - The present invention is a method for detecting and destroying cancer tumors. The method is based on the concept of associating a linking protein or linking peptide such as, but not limited to, annexin V or other annexins to single-walled carbon nanotubes (SWNT) to form a protein-SWNT complex. Said linking protein or peptide can selectively bind to cancerous cells, especially tumor vasculature endothelial cells, rather than to healthy ones by binding to cancer-specific external receptors such as anionic phospholipids including phosphatidylserine expressed on the outer surfaces of cancer cells only. Irradiation of bound SWNTs with specific wavelength is then used to detect and destroy those cells to which the SWNTs are bound via the linking protein or peptide thereby destroying the tumor or cancer cells. | 09-18-2008 |
| 20080280831 | Chimeric proteins with phosphatidylserine binding domains - Chimeric proteins comprising soluble Tissue Factor (sTF) and another subunit (e.g., annexin V) are described. The proteins promote blood clotting and/or inhibit cancer by targeting sTF to specific receptors such as phosphatidylserine (PS) on activated cells. These chimeric proteins are useful in treating patients with excessive bleeding due to inborn problems, drug therapy, trauma or surgery and/or as an anti-cancer therapy, for example by causing blood vessels feeding cancers to become clotted, thereby preventing adequate flow of blood to a tumor, which in turn will lead to tumor inhibition and death or may be used in a therapy to cause clotting within blood vessels that pose a threat in the subject in non-cancerous conditions. | 11-13-2008 |
| 20090304666 | CONJUGATE FOR THE SPECIFIC TARGETING OF ANTICANCER AGENTS TO TUMOR CELLS OR TUMOR VASCULATURE AND PRODUCTION THEREOF - A conjugate is disclosed herein, wherein the conjugate includes a ligand having the ability to specifically and stably bind to an external receptor or binding site on a tumor vasculature endothelial cell, wherein the external receptor or binding site is specific for tumor vasculature endothelial cells. The conjugate also includes an anticancer agent that is selectively toxic to cancer cells operatively attached to the ligand. The anticancer agent may be L-methioninase. Pharmaceutical compositions comprising the conjugate are also disclosed, as well as methods of treating a cancer tumor or cancer cells with a therapeutically effective amount of the conjugate. | 12-10-2009 |
| 20110002978 | ENZYME PRODRUG CANCER THERAPY SELECTIVELY TARGETED TO TUMOR CELLS OR TUMOR VASCULATURE AND METHODS OF PRODUCTION AND USE THEREOF - Conjugates for use in an enzyme prodrug cancer therapy treatment are provided. | 01-06-2011 |